Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

May 20th 2020

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 19th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. O'Donnell on Up-front Triplets in Multiple Myeloma

May 16th 2020

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Community Advice: SQ Formulation of Daratumumab

May 13th 2020

Real-World Experience With SQ Monoclonal Antibodies

May 13th 2020

Study Overview: COLUMBA and PLEIADES

May 13th 2020

Infusion-Related Adverse Events

May 13th 2020

Medication Supplements Prior to IV Administration

May 13th 2020

Intravenous Administration and Hepatitis

May 13th 2020

The Intravenous Administration of Monoclonal Antibodies

May 13th 2020

Mateos Spotlights Significance of Subcutaneous Daratumumab Approval in Myeloma

May 13th 2020

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

FDA: Idecabtagene Vicleucel Myeloma BLA Needs Further Details

May 13th 2020

The FDA has issued a Refusal to File letter to Bristol Myers Squibb and bluebird bio, Inc., regarding their Biologics License Application (BLA) for the BCMA-directed CAR T-cell therapy decabtagene vicleucel.

FDA: Idecabtagene Vicleucel Myeloma BLA Needs Further Details

May 13th 2020

The FDA has requested additional details before accepting a biologics license application for idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Mateos Spotlights Significance of Subcutaneous Daratumumab Approval in Myeloma

May 13th 2020

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

Dr. Braunstein on Updated Results of the GRIFFIN Trial in Multiple Myeloma

May 13th 2020

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Isatuximab Plus Carfilzomib/Dexamethasone Improves PFS in Phase 3 Myeloma Trial

May 12th 2020

Adding isatuximab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed multiple myeloma, meeting the primary end point of the phase 3 IKEMA trial.

Dr. Anderson on Recent Advances With Novel Therapies in Multiple Myeloma

May 12th 2020

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Talking Tumors: Exploring Management Strategies in Multiple Myeloma

May 11th 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Dr. Braunstein on Quadruplet Therapies in Multiple Myeloma

May 9th 2020

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

May 4th 2020

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.